The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]
Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib [BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA]
[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]
[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]
vemurafenib results in increased secretion of CCL2 protein vemurafenib results in increased expression of CCL2 mRNA CCL2 protein results in decreased susceptibility to vemurafenib
CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] vemurafenib results in decreased expression of CCND1 protein
vemurafenib results in decreased expression of CD70 protein [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]
[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]
[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]
[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]
[MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]
KRAS protein mutant form affects the susceptibility to vemurafenib [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]; Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein] vemurafenib results in increased phosphorylation of MAPK1 protein vemurafenib results in decreased phosphorylation of MAPK1 protein
vemurafenib results in decreased phosphorylation of MAPK3 protein vemurafenib results in increased phosphorylation of MAPK3 protein [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
[MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]
vemurafenib results in decreased expression of MYC protein (+)-JQ1 compound promotes the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; vemurafenib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
NRAS protein mutant form affects the susceptibility to vemurafenib [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein
[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [Vemurafenib co-treated with 3,5-bis((4-nitrophenyl)methylidene)-1-prop-2-enoylpiperidin-4-one] results in increased cleavage of PARP1 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]
RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]
[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA; [vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]]; TSHB protein promotes the reaction [[vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]
Vemurafenib results in decreased cleavage of SREBF1 protein [BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein] Vemurafenib results in decreased expression of SREBF1 mRNA alternative form
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]
[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]
[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]
[YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK1 protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK3 protein] vemurafenib affects the localization of YAP1 protein
[venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]
BBC3 protein affects the susceptibility to venetoclax 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [BBC3 protein affects the susceptibility to venetoclax]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]
venetoclax results in decreased activity of BCL2 protein venetoclax results in decreased expression of BCL2 protein [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of BCL2 protein; [mivebresib co-treated with venetoclax] results in decreased expression of BCL2 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]
[venetoclax co-treated with sepantronium] results in increased cleavage of CASP3 protein; venetoclax inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of CASP3 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of CASP3 protein]
venetoclax results in decreased expression of FLT3 protein 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- promotes the reaction [venetoclax results in decreased expression of FLT3 protein]; [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of FLT3 protein
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK1 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK1 protein
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK3 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK3 protein
venetoclax results in increased expression of MCL1 protein venetoclax results in decreased expression of MCL1 protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; [mivebresib co-treated with venetoclax] results in decreased expression of MCL1 protein; [sepantronium co-treated with venetoclax] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]
[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 protein; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 protein
[mivebresib co-treated with venetoclax] results in increased cleavage of PARP1 protein; [venetoclax co-treated with sepantronium] results in increased cleavage of PARP1 protein; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of PARP1 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of PARP1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein] PMAIP1 protein affects the susceptibility to venetoclax venetoclax results in increased expression of PMAIP1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of and results in increased stability of SP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein; [venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]
browse the term
